Posted by Michael Wonder on 07 Aug 2018
Government looks to include biosimilars in price controls
7 August 2018 - The government has launched consultation on proposed changes to the statutory scheme for pharmaceutical pricing that would include biosimilars in the scope of its price controls.
The statutory scheme covers those companies who don’t sign on to the voluntary Pharmaceutical Price Regulation Scheme (PPRS). To coincide with the new PPRS scheme, expected to come into force after the current scheme expires on 31 December 2018, the government is proposing changes to the statutory scheme from the beginning of 2019.
One change would be to include all biological medicinal products (including biosimilars) within the scope of health service medicines captured by the payment mechanism, price controls and information requirements.
